anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Routine coagulation tests such as Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) are relatively insensitive measures of the activity of fondaparinux sodium and international standards of heparin or LMWH are not calibrators to measure anti-Factor Xa activity of fondaparinux sodium. If unexpected changes in coagulation parameters or major bleeding occur during therapy with fondaparinux sodium, discontinue fondaparinux sodium. In postmarketing experience, isolated occurrences of aPTT elevations have been reported following administration of fondaparinux sodium [see Adverse Reactions (6.5)]. 

Periodic routine complete blood counts (including platelet count), serum creatinine level, and stool occult blood tests are recommended during the course of treatment with fondaparinux sodium. 

The anti-Factor Xa activity of fondaparinux sodium can be measured by anti-Xa assay using the appropriate calibrator (fondaparinux). The activity of fondaparinux sodium is expressed in milligrams (mg) of the fondaparinux and cannot be compared with activities of heparin or low molecular weight heparins. [see Clinical Pharmacology (12.2, 12.3)]
OBJECTIVE: This study aimed to develop and validate a nomogram for assessing the risk of nosocomial infections among obstetric inpatients, providing a valuable reference for predicting and mitigating the risk of postpartum infections.
METHODS: A retrospective observational study was performed on a cohort of 28,608 obstetric patients admitted for childbirth between 2017 and 2022. Data from the year 2022, comprising 4,153 inpatients, were utilized for model validation. Univariable and multivariable stepwise logistic regression analyses were employed to identify the factors influencing nosocomial infections among obstetric inpatients. A nomogram was subsequently developed based on the final predictive model. The receiver operating characteristic (ROC) curve was utilized to calculate the area under the curve (AUC) to evaluate the predictive accuracy of the nomogram in both the training and validation datasets.
RESULTS: The gestational weeks > = 37, prenatal anemia, prenatal hypoproteinemia, premature rupture of membranes (PROM), cesarean sction, operative delivery, adverse birth outcomes, length of hospitalization (days) > 5, CVC use and catheterization of ureter were included in the ultimate prediction model. The AUC of the nomogram was 0.828 (0.823, 0.833) in the training dataset and 0.855 (0.844, 0.865) in the validation dataset.
CONCLUSION: Through a large-scale retrospective study conducted in China, we developed and independently validated a nomogram to enable personalized postpartum infections risk estimates for obstetric inpatients. Its clinical application can facilitate early identification of high-risk groups, enabling timely infection prevention and control measures.
PROBLEM TO BE SOLVED: To suppress isomerization to an inert picro isomer and purify etoposide in high purity by thermally treating a solution of an organic solvent (e.g. an alcohol-based solvent) of etoposide widely used as an antitumor agent in the presence of an organic acid such as citric acid. SOLUTION: Etoposide (4'-demethyl 4 epipodophyllotoxin-β-D-ethylidene- glucoside) represented by the formula (Me is methyl) is heated and dissolved in an organic solvent (e.g. methanol) such as an alcohol based solvent and an organic acid (e.g. citric acid) and active carbon are added to the solution and the mixture is allowed to stand for 10min and the active carbon is filtered and the filtrate is subjected to heat treatment on an oil bath having about 70 deg.C bath temperature for 19hr. Thereby, isomerization of the etoposide to an inert picro isomer is suppressed to provide the objective etoposide purified in high purity.
In the "dusting" arm, the ureteroscope will be advanced into the kidney or ureter over an access wire without an access sheath in place. The identified stone will be dusted using a 200 micron Moses laser fiber at a setting of 0.3-0.6 J and 50-120 Hz using the Moses 2.0 laser system. Stone dusting will continue until the surgeon feels the fragments are all negligible in size and would be able to pass. One small piece will be extracted for analysis and the remainder will be left to pass spontaneously. If there is no evidence of injury or swelling of the ureter at the conclusion of the case a stent will be omitted.
The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
PURPOSE: A neuritin protein for treating stress and depression is provided to remarkably enhance spine density in nerve cells and to improve emotional function. CONSTITUTION: A composition for treating depression or stress contains neuritin(CPG15) protein which enhances spine density. The protein has an amino acid sequence of sequence number 1. The composition contains nucleic acid with a nucleotide encoding the protein. The nucleic acid is a recombinant expression vector with the nucleotide sequence. The recombinant expression vector is a recombinant virus vector. The recombinant virus vector is recombinant retrovirus, adenovirus, or lentivirus. A method for enhancing spine density comprises a step of administering a composition containing neuritis polypeptide, a fragment or analogue thereof, and a carrier.
1. Use of biogenic estrogen sulfamates for the production of pharmaceutical agents for oral, intermittent administration for hormone replacement therapy, whereby the individual administrations have an interval of 2 to 40 days. 2. Use of biogenic estrogen sulfamates according to claim 1, characterized in that the biogenic estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate or an N-acylsulfamate of estrone, estradiol or estriol with up to 7 C atoms in the acyl chain or a combination of two or more of the above-mentioned active ingredients. 3. Use according to one of the preceding claims, wherein in addition at least one gestagen is administered. 4. Use according to claim 3, wherein the gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a combination of two or more of the above-mentioned active ingredients. 5. Use according to claim 4, wherein the gestagen is administered continuously in the form of an implant or in the form of an intrauterine release system (IUD) or in combination with the above-mentioned types of administration. 6. Use according to one of claims 1 to 5, wherein the administration interval is 5 to l0 days, and the individual dosage unit for the administration interval is 0.5-5.0 mg of biogenic estrogen sulfamate. 7. Use according to one of claims 1 to 5, wherein the administration interval is 20 to 40 days, and the individual dosage unit for the administration interval is 2.0-20.0 mg of biogenic estrogen sulfamate. 8. Pharmaceutical composition that contains at least one biogenic estrogen, optionally combined with pharmaceutically compatible adjuvants and vehicles, wherein the individual dosage unit is 20-300 mug of biogenic estrogen sulfamate for an administration interval of 1 to 3 days, 0.5-5.0 mg of biogenic estrogen sulfamate for an administration interval of 5 to 10 days or 2.0-20 mg of biogenic estrogen sulfamate for an administration interval of 20 to 40 days. 9. Pharmaceutical composition according to claim 8, wherein the biogenic estrogen sulfamate is estrone sulfamate, estradiol sulfamate, estriol sulfamate or an N-acylsulfamate of estrone, estradiol or estriol with up to 7 C atoms in the acyl chain or a combination of two or more of the above-mentioned active ingredients. 10. Pharmaceutical composition according to one of claims 8 and/or 9, wherein in addition at least one gestagen is administered. 11. Pharmaceutical composition according to claim 10, wherein the gestagen is levonorgestrel, desogestrel, norethisterone, medroxyprogesterone acetate, megestrol, cyproterone acetate, chlormadinone acetate, dienogest, drospirenone or a combination of two or more of the abovementioned active ingredients. 12. Pharmaceutical composition according to claim 11, wherein the gestagen is administered continuously in the form of an implant or in the form of an intrauterine release system (IUD) or combined with the above-mentioned types of administration.
BACKGROUND: IL-26 is a key mediator of pulmonary host defense given its abundant expression in human airways and its established antibacterial properties. Moreover, recent studies indicate that IL-26 can also inhibit viral replication. Along these lines, we have previously reported an increase in the plasma concentration of IL-26 among patients with acute COVID-19 that is linked to harmful hyperinflammation. Nevertheless, it is still unclear whether this systemic increase in IL-26 relates to disease severity, sex, comorbidities, viral load, or the innate immune response in acute COVID-19.
METHODS: IL-26 was quantified using ELISA in plasma samples from a large cohort of well-characterized patients with acute COVID-19 (n=178) and healthy controls (n=30). The plasma concentrations of SARS-CoV-2 nucleocapsid and spike protein, as well as those of IFN-α2a, IFN-β, and IFN-γ, were determined using electrochemiluminescence immunoassay. The concentration of double-stranded DNA was determined using fluorometry.
RESULTS: The plasma concentration of IL-26 was increased in patients with severe/critical COVID-19, particularly among males and patients with comorbid obstructive lung disease. Moreover, the concentration of IL-26 displayed positive correlations with length of hospital stay, as well as with systemic markers of viral load, antiviral immunity, and extracellular DNA.
CONCLUSIONS: Systemic IL-26 is involved in severe COVID-19, especially in males and patients with comorbid obstructive lung disease. These findings argue that systemic IL-26 has pathogenic and antiviral relevance, as well as biomarker potential.
Background: Pain relief in the intrapartum period is important for maternal-fetal health. Studies in the literature have generally focused on the first stage of labor. When the labor process is considered as a whole, women may also experience pain during episiotomy repair. In recent years, traditional methods have become more preferred due to the side effects of pharmacologic treatments to relieve pain symptoms. Acupressure, one of the traditional methods, is used to relieve pain and various symptoms by applying pressure on acupuncture points with manual techniques. In the literature, LI4 acupressure is applied to relieve pain symptoms caused by various reasons. However, among the studies reviewed, no study was found to investigate the effect of LI4 acupressure application on perineal pain perceived during episiotomy repair and postpartum comfort level.

Objective: The study was planned to evaluate the effect of LI4 acupressure on perineal pain and postpartum comfort during episiotomy repair.

Materials and Methods: Our study was designed as a randomized, controlled, single-blind, placebo-designed experimental study. The study will be conducted in the maternity ward of Istanbul SBÜ Kanuni Sultan Süleyman Training and Research Hospital between May 1, 2024 and October 20, 2025. The sample of the study will consist of a total of 90 pregnant women (experimental group= 30, control group= 30, placebo group= 30) who were hospitalized in the maternity ward and agreed to participate in the study. During the episiotomy repair, the LI4 acupuncture point on the right hand of the participants in the experimental group will be compressed 10 times for 30 s in succession, followed by a 10 s break. The procedure will start with the first suturing. Vital signs will be taken just before the first suturing and after the suturing is completed. A different point 1-1.5 cm away from the LI4 acupuncture point on the right hand of the participants in the placebo group will be compressed. No intervention will be applied to the control group. Data will be obtained using the Pregnancy Identification Form, Visual Comparison Scale, Postpartum Comfort Scale, Labor Monitoring Form and McGill Pain Scale Short Form. The data obtained from the study will be analyzed in SPSS 23 statistical program in computer environment. In the evaluation of the data, mean, standard deviation, minimum and maximum values, frequency and percentage calculations, t-test and chi-square test will be used.
Inflammatory arthritis commonly initiates in the soft tissues lining the joint. This lining swells, as do the cells in it and inside the joint fluid, producing chemicals that induce inflammation signs such as heat, redness, and swelling. MicroRNA (miRNA), a subset of non-coding small RNA molecules, post-transcriptionally controls gene expression by targeting their messenger RNA. MiRNAs modulate approximately 1/3 of the human genome with their multiple targets. Recently, they have been extensively studied as key modulators of the innate and adaptive immune systems in diseases such as allergic disorders, types of cancer, and cardiovascular diseases. However, research on the different inflammatory joint diseases, such as rheumatoid arthritis, gout, Lyme disease, ankylosing spondylitis, and psoriatic arthritis, remains in its infancy. This review presents a deeper understanding of miRNA biogenesis and the functions of miRNAs in modulating the immune and inflammatory responses in the above-mentioned inflammatory joint diseases. According to the literature, it has been demonstrated that the development of inflammatory joint disorders is closely related to different miRNAs and their specific regulatory mechanisms. Furthermore, they may present as possible prognostic and diagnostic biomarkers for all diseases and may help in developing a therapeutic response. However, further studies are needed to determine whether manipulating miRNAs can influence the development and progression of inflammatory joint disorders.
Disclosed are expressible reverse gene constructs, and oligonucleotides, which are characterized by the ability to hybridize with an Ii mRNA molecule, thereby inhibiting translation of the Ii mRNA molecule.  These compositions are referred to generally as inhibitors of Ii expression. Also disclosed are MHC class II-positive antigen presenting cells containing an inhibitor of Ii expression. A particularly important class of MHC class II-positive antigen presenting cells are malignant MHC class II-positive antigen presenting cells (e.g., leukemia, lymphoma and melanoma). Also disclosed are methods which result in the display of an autodeterminant peptide, in association with an MHC class II protein, on the surface of an MHC class II-positive antigen presenting cell. In such methods, a specific inhibitor of Ii synthesis is introduced into an MHC class II-positive antigen presenting cell.  The specific inhibitor functions, directly or indirectly, through the formation of a duplex molecule with mRNA encoding Ii. The formation of the duplex molecule functions to inhibit Ii synthesis at the translational level. Also disclosed are therapeutic methods for the treatment of malignancy in an MHC class II-positive antigen presenting cell, and autodeterminant peptides which are isolated from an MHC class II-positive antigen presenting cell.
Participants will be randomly assigned. Control group:57 participants Follow-up for 4 weeks. Urine samples of 24 h before and after the educational program will be analyzed.
The application provides a compound preparation prepared from clindamycin and cimetidine and a preparation method thereof. The active ingredients of the compound comprise clindamycin and cimetidine, and the proportion is 0.075-1.2: 0.01 to 0.4. The raw material medicaments are taken according to the corresponding parts by weight, and are added with proper auxiliary materials according to the preparation method of corresponding pharmaceutics, so that the raw material medicaments can be respectively prepared into granules, dry suspensions, tablets, capsules, injections and other formulations. The action mechanism of the antibacterial peptide is to inhibit the synthesis of bacterial protein to generate antibacterial action, and is mainly used for infection caused by gram-positive cocci and anaerobic bacteria. Cimetidine is a liver drug enzyme inhibitor, can delay the metabolism of the combined drug, and improve the blood concentration of the combined drug so as to improve the curative effect of the combined drug; meanwhile, cimetidine can also inhibit gastric acid secretion to relieve the stimulation of clindamycin to stomach. The two are prepared into a compound preparation, the effect of treating infection caused by sensitive bacteria is good, the side effect is low, the medication is safe, the taking is convenient, and the application effect is good.
There is provided a computer-implemented method for generating a care plan for a subject. A plurality of care plans stored in one or more databases are accessed ( 202 ). The plurality of care plans are grouped into a plurality of care plan categories based on a similarity measure between one or more attributes of the plurality of care plans. Each of the plurality of care plans is associated with a reference subject. A care plan category for the subject is identified from the plurality of care plan categories using a trained classifier ( 204 ). A care plan for the subject is generated ( 206 ) based on the one or more care plans that are grouped into the identified care plan category, by maximizing a similarity measure between one or more attributes of the subject and one or more corresponding attributes of the reference subjects.
Hot flashes are the most severe and fourth most prevalent menopausal symptom reported by women with breast cancer. Hot flashes affect over 65% of this population, with 59% rating the symptom as severe and 44% reporting they are extremely distressed by the symptom. Despite the high prevalence, severity and distress associated with this symptom, the scientific basis for managing hot flashes in women with breast cancer is limited. This randomized, double-blind, placebo-controlled crossover trial examines the effectiveness and toxicity of sustained release venlafaxine hydrochloride (37.5 mg po qd) on hot flashes in women following treatment for breast cancer. Venlafaxine is a phenylethylamine derivative that potently inhibits the reuptake of neuronal serotonin and norepinephrine and weakly inhibits the reuptake of dopamine. A secondary aim of this project is to examine the impact of hot flashes on psychological, behavioral, and physical outcomes. This study is based on the Wickham Symptom Management Model which depicts interrelationships between symptoms, symptom management strategies, and symptom management outcomes. Participants (n = 80) who are at least one month post-completion of surgery, radiation, and/or chemotherapy and who have been on tamoxifen (if prescribed) for at least six weeks will complete a two-week baseline hot flash assessment and be randomized to one arm of the crossover trial. At the end of the first six-week arm, participants will crossover to the opposite study arm for an additional six weeks. Outcomes to be assessed include effectiveness of the intervention (hot flash frequency, severity, distress and magnitude), toxicity of the intervention (subjective preference, side effects), psychological outcomes (mood disturbance), behavioral outcomes (quality of life, interference with daily activities) and physical outcomes (fatigue and sleep disturbance). Hot flashes will be measured daily, using a subjective, prospective diary methodology, and weekly, using objective state-of-the art 24-hour physiological monitoring of sternal skin conductance. Other outcomes will be measured weekly. Compliance with the intervention/placebo will be assessed weekly using medication blister pack cards. Timing of outcome assessments is based on limitations of the physiological monitoring device and expected timing of treatment effects. Summary statistics (i.e., mean, slope, maximum response, range, proportion, achievable difference) will be used to effectively reduce the design to a 2 X 2 crossover and data will be analyzed accordingly (i.e., t-tests, linear regression, GEE, mixed model). Study findings will significantly contribute to the scientific basis of hot flash management in women following treatment for breast cancer.
This invention discloses a technique for improving the pharmaceutical quality of protocorm in Dendrobium candidum by using MF24 (Mycena sp.). The technique comprises: (1) culturing protocorm in Dendrobium candidum and MF24 (Mycena sp.), respectively; (2) manufacturing MF24 (Mycena sp.) into inducer, and adding into protocorm in Dendrobium candidum for co-culture. The method can rapidly culture protocorm in Dendrobium candidum in a large scale. The cultured protocorm in Dendrobium candidum has obviously increased contents of polysaccharides and alkaloids, and has higher immunoactivity.
For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
BACKGROUND: Ischemia-induced cellular damage and stress responses significantly impact cellular viability and function. Icariin (ICA), known for its protective effects, has been studied to understand its role in mitigating oxygen-glucose deprivation/reperfusion (OGD/R)-induced endoplasmic reticulum (ER) stress and ferroptosis in H9C2 cardiomyoblast cells.
METHODS: We employed an in vitro OGD/R model using H9C2 cells. ICA's effects were analyzed across multiple concentrations. Key indicators of ER stress, autophagy, and ferroptosis-including markers like Bip, PERK, IRE1, ATF6, P62, FTH1, LC3II/LC3I, and NCOA4-were assessed using Western blotting, electron microscopy, and biochemical assays. Additionally, the role of the IRE1/JNK pathway in mitochondrial dynamics and its influence on mitochondrial dynamics protein was explored through specific inhibition and activation experiments.
RESULTS: ICA significantly reduced the activation of UPR pathways, decreased autophagic vacuole formation, and maintained cell viability in response to OGD/R and Erastin-induced ferroptosis. These protective effects were associated with modulated autophagic processes, reduced lipid peroxidation, and decreased ferrous ion accumulation. Inhibition of the IRE1/JNK pathway and subsequent Drp1 activity demonstrated reduced mitochondrial recruitment and mitophagy, correlating with decreased ferroptosis markers and improved cell survival.
CONCLUSION: Our findings highlight ICA's potential in modulating IRE1/JNK pathway, autophagy, providing a therapeutic avenue for mitigating ferroptosis in myocardial ischemia-reperfusion injury (MIRI).